BioMarin Pharmaceutical Inc.

BMRN

US09061G1013

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 10/02/2026 am IST			5-day change	1st Jan Change
57.81 ^USD	-0.55%		-0.24%	-2.73%

26/01	Sector Update: Health Care Stocks Mixed Premarket Monday	MT
26/01	Biomarin Pharmaceutical Inc. Announces $850 Million of Senior Unsecured Notes Due 2034	CI

Sector Update: Health Care

Published on 12/19/2025 at 07:29 pm IST

MT Newswires

Latest news about BioMarin Pharmaceutical Inc.

26/01	Sector Update: Health Care Stocks Mixed Premarket Monday	MT
26/01	Biomarin Pharmaceutical Inc. Announces $850 Million of Senior Unsecured Notes Due 2034	CI
26/01	BioMarin Pharmaceutical Plans $850 Million Notes Offering, Lines Up $2 Billion Syndicated Loan	MT
26/01	BioMarin announces proposed private offering of senior notes and syndication of new senior secured term loan facility	RE
21/01	When America Starts to Feel Like a Risky Asset
20/01	Canaccord Genuity Upgrades BioMarin Pharmaceutical to Buy From Hold, Adjusts Price Target to $98 From $84	MT
20/01	Greenland, Tariffs, and the Quiet Revolt of the Bond Market
20/01	Analyst recommendations: Intel, Philip Morris, Duolingo, Netflix, SanDisk…
14/01	BioMarin Pharmaceuticals Aims for Sustained Growth in 2026, Wedbush Says	MT
13/01	BioMarin Pharmaceutical Reports Preliminary 2025 Revenue, Details Asset Write-Down	MT
13/01	Biomarin Pharmaceutical Inc estimates $3.2 billion in total revenues for FY - SEC filing	RE
13/01	BioMarin Pharmaceutical Names Arpit Dave Chief Digital and Information Officer	MT
13/01	BioMarin Pharmaceutical Inc. Appoints Arpit Davé as Executive Vice President and Chief Digital and Information Officer	CI
13/01	BioMarin Pharmaceutical Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 11:15 AM
08/01	Veeva Systems, BioMarin Pharmaceutical Enter Long-Term Partnership	MT
08/01	Veeva and Biomarin form long-term strategic partnership	RE
22/12	Truist Securities Lifts BioMarin Pharmaceutical Price Target to $100 From $80, Maintains Buy Rating	MT
22/12	BioMarin Pharmaceutical Inc. Announces its Decision to Discontinue Development of BMN349	CI
20/12	Health Care Up Amid Deal Activity -- Health Care Roundup	DJ
20/12	Sector Update: Health Care Stocks Rise Late Afternoon	MT
20/12	Sector Update: Health Care Stocks Higher Friday Afternoon	MT
19/12	Sector Update: Health Care	MT
19/12	Top Midday Gainers	MT
19/12	Top Midday Stories: Oracle, Others Form JV to Oversee TikTok in US; More Drugmakers to Announce US Drug Price Deals	MT
19/12	BioMarin Pharmaceutical Inc. submitted a non-binding indication of interest to acquire Amicus Therapeutics, Inc. from The Vanguard Group, Inc., Wellington Management Group LLP, BlackRock, Inc., William Blair Investment Management, LLC, and others for $4.7 billion.	CI

Chart BioMarin Pharmaceutical Inc.

Duration

Period

BMRN: Dynamic Chart

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Employees

3,040

Sector

Pharmaceuticals

Calendar

25/02 - Q4 2025 Earnings Release (Projected)

More about the company